BD111

BD111 is an experimental CRISPR gene-editing treatment injected into the cornea for recurrent HSV-1 stromal keratitis. It is an eye-specific program, not a tested treatment for genital HSV, HSV-2, oral herpes, or HSV throughout the body.

Three severe cases have been published, and a randomized Phase 2 study was later started. The early cases are important proof-of-concept evidence, but they do not show that BD111 clears latent HSV from the trigeminal ganglion or cures HSV infection.

BD111 uses a lentiviral-like particle to carry SpCas9 messenger RNA and guide-RNA instructions into corneal tissue. The editing system is designed to cut HSV-1 genes needed for viral replication.

The product is also described as HELP, short for HSV-1-erasing lentiviral particles, in the early human paper. The later sponsor trials use the BD111 name. Exact formulation continuity across every research and clinical lot is not fully public.

The program asks whether a one-time local corneal injection can be delivered safely and improve outcomes for people with recurrent HSV-1 stromal keratitis. The current Phase 2 compares BD111 plus standard drug therapy with a sham injection plus the same standard therapy.

The first human study treated three people with severe refractory keratitis and acute corneal perforation. Each received one injection during corneal-transplant surgery. The study had no control group, and the surgery and postoperative care make it impossible to isolate BD111's effect from the procedure.

A separate formal Phase 1 dose-escalation study was later opened, followed by a planned 40-person randomized Phase 2a study. BDgene reported the first Phase 2 participant was dosed in July 2025, and the registry listed the study as recruiting as of September 1, 2026.

In the three published cases, investigators reported no recurrence through last visits of 14, 18, and 21 months. Tear-swab HSV-1 tests were negative at most later visits, although one participant had positive tests during the first month before later tests became negative.

The investigators reported no systemic adverse events and did not detect edits at the candidate off-target sites they tested. Ocular complications did occur; the authors attributed most to the severe disease and high-risk transplantation but said a contribution from the experimental treatment could not be fully excluded.

These observations are descriptive. Three uncontrolled cases cannot establish how much BD111 caused the later viral-test or recurrence pattern, how often the result would occur, or what uncommon and delayed risks might appear.

BD111 is reasonably categorized as a potentially curative approach because it directly targets viral DNA rather than only suppressing replication. The qualifier matters: human evidence is local to the treated eye, and a potentially curative mechanism is not a demonstrated cure.

Evidence maturity remains early human. Starting a controlled Phase 2 trial advances the development stage, but it does not supply controlled efficacy evidence until results are available.

BD111 is in an initiated Phase 2a program for recurrent HSV-1 stromal keratitis in China. It remained investigational, with no approval, general availability, or expanded-access record identified through September 1, 2026.

The important next evidence is not another first-dose announcement. It is updated Phase 1 reporting and controlled Phase 2 data on the combined clinical and viral endpoint, recurrence, vision, safety, vector persistence, immune responses, and off-target testing.